Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Soliqua

National Institute for Health and Care Excellence NICE logo

NICE reverses negative guidance for Forxiga in diabetes

Final draft guidance backs the use of BMS/AstraZeneca’s SGLT-2 inhibitor in certain patients

- PMLiVE

Gilead launches combination HIV pill in UK and Germany

Stribild is approved in EU as once-daily single tablet

- PMLiVE

A look back at Sanofi’s merger with Synthélabo

This month, in 1999: How two pharma companies came together to create a giant

Sanofi reception

Sanofi reconsiders closure plans in Toulouse after government pressure

Report says research site can remain open with minimal job losses

Sanofi reception

Sanofi plans to file JAK2 inhibitor after positive phase III

Aiming for approval in blood cancer myelofibrosis

- PMLiVE

Sanofi partners with PatientsLikeMe to promote its clinical trials

Online patient community will match patients to the pharma company's trials

Sanofi reception

Sanofi fined for slamming Plavix generics

Faces €40.6m penalty for telling doctors generic copies were not suitable substitutes for blockbuster antiplatelet drug

- PMLiVE

Sanofi appoints Pascale Witz and Peter Guenter

They will lead the pharma company's two new commercial organisations

- PMLiVE

Merck & Co enters $430m diabetes deal with Abide

Will target group of enzymes known as serine hydrolases

Sanofi reception

Sanofi predicts return to growth in second half

But first quarter net income drops by a third

- PMLiVE

Sanofi launches diabetes drug Lyxumia in the UK

Says drug could make multimillion pound savings for the NHS

- PMLiVE

Interview: Peter Meeus, Novo Nordisk

The managing director of Novo Nordisk UK discusses how education and new partnerships are helping fight the battle against the country’s worsening diabetes crisis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links